GDTC vs. PMVP, SCYX, ETON, RLMD, ORMP, CMRX, IFRX, HILS, ASMB, and SLS
Should you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include PMV Pharmaceuticals (PMVP), SCYNEXIS (SCYX), Eton Pharmaceuticals (ETON), Relmada Therapeutics (RLMD), Oramed Pharmaceuticals (ORMP), Chimerix (CMRX), InflaRx (IFRX), Hillstream BioPharma (HILS), Assembly Biosciences (ASMB), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical preparations" industry.
PMV Pharmaceuticals (NASDAQ:PMVP) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, community ranking, earnings, risk, institutional ownership, dividends and valuation.
PMV Pharmaceuticals currently has a consensus price target of $5.75, indicating a potential upside of 215.93%. CytoMed Therapeutics has a consensus price target of $5.00, indicating a potential upside of 131.48%. Given CytoMed Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe PMV Pharmaceuticals is more favorable than CytoMed Therapeutics.
PMV Pharmaceuticals received 19 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 60.00% of users gave PMV Pharmaceuticals an outperform vote.
90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, PMV Pharmaceuticals had 3 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 5 mentions for PMV Pharmaceuticals and 2 mentions for CytoMed Therapeutics. PMV Pharmaceuticals' average media sentiment score of 1.44 beat CytoMed Therapeutics' score of 0.72 indicating that CytoMed Therapeutics is being referred to more favorably in the news media.
PMV Pharmaceuticals' return on equity of 0.00% beat CytoMed Therapeutics' return on equity.
Summary
PMV Pharmaceuticals beats CytoMed Therapeutics on 8 of the 13 factors compared between the two stocks.
Get CytoMed Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GDTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CytoMed Therapeutics Competitors List
Related Companies and Tools
